Results 181 to 190 of about 790,096 (261)

Impact on hospitals of price reductions for physician-administered biologics. [PDF]

Health Aff Sch
Robinson JC, Thomson M, Kosorukov AD, Whaley CM.   +3 more
europepmc   +1 more source

Budget impact analysis of the introduction of ranibizumab's biosimilar to the Jordanian joint procurement system. [PDF]

Front Public Health
Hamida JA, Alkhatib NS, Hammour KA, Halloush S, Kurdi A, Balkhi B, Alfayez OM, Mousa R.   +7 more
europepmc   +1 more source

A landscape of sequence variants in 51 commercial antibody therapeutics. [PDF]

Antib Ther
Xu G, Wu G, Cui C, Wei S, Duan M, Cui Y, Mei YT, Yu C, Wang L.   +8 more
europepmc   +1 more source

FDA's Approval Summary of the First Biosimilar to Natalizumab for the Treatment of Multiple Sclerosis and Crohn's Disease. [PDF]

J Clin Pharmacol
Delvadia PR, Nookala AR, Gottipati G, Sabarinath S, Uppoor RS, Mehta MU, Du X, Wang YC, Dokmanovic M, Myers R, Stevens J, Baldassari L, Lee P, Jawidzik L, Apparaju S, Seo S, Brahme NN, Schrieber SJ.   +17 more
europepmc   +1 more source

The Future of Biologics: Lessons from Hatch-Waxman. [PDF]

Ther Innov Regul Sci
Miller BJ, Woodcock J.
europepmc   +1 more source

Net Present Value Impact of FDA's Phase 3 Waivers on Monoclonal Antibody Biosimilar Development. [PDF]

Biologics
Ranbhor R, Kulkarni P.
europepmc   +1 more source

Ten-Year Public Expenditure Savings Associated with TNF Inhibitor Biosimilars under Australia's Pharmaceutical Benefits Scheme. [PDF]

Clin Pharmacol Ther
Yiu CH, Ianni BD, Day RO, Raubenheimer J, Lu CY.   +4 more
europepmc   +1 more source

Shaping the future of retinal care in India: Anti-VEGF therapy now and beyond. [PDF]

Indian J Ophthalmol
Karpe A, Narula R, Shroff D, Roy A.
europepmc   +1 more source

International approval of Chinese pharmaceuticals: a USA-anchored analysis with comparative insights from Europe and other markets. [PDF]

EClinicalMedicine
Xu Z, Jenei K, Sullivan R.
europepmc   +1 more source

Evolution of Approaches to the Development, Life Cycle Control, and Interchangeability of Veterinary Biosimilars Based on Hemoproteins (with a Focus on Cytochrome C). [PDF]

Pharmaceuticals (Basel)
Ponamarev VS.
europepmc   +1 more source